140.03
Moderna Inc stock is currently priced at $140.03, with a 24-hour trading volume of 3.56M.
It has seen a -3.58% decreased in the last 24 hours and a +9.13% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $146.3 pivot point. If it approaches the $139.8 support level, significant changes may occur.
Previous Close:
$145.23
Open:
$142.67
24h Volume:
3.56M
Market Cap:
$53.67B
Revenue:
$5.08B
Net Income/Loss:
$-5.97B
P/E Ratio:
-14.98
EPS:
-9.35
Net Cash Flow:
$-3.67B
1W Performance:
-7.27%
1M Performance:
+9.13%
6M Performance:
+63.07%
1Y Performance:
+11.09%
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
617-714-6500
Address
200 Technology Square, Cambridge
Moderna Inc Stock (MRNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-29-23 | Initiated | Canaccord Genuity | Hold |
Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
Jul-24-23 | Initiated | William Blair | Mkt Perform |
Jul-14-23 | Initiated | HSBC Securities | Reduce |
Jun-26-23 | Upgrade | UBS | Neutral → Buy |
Apr-26-23 | Initiated | Guggenheim | Neutral |
Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-21-22 | Initiated | UBS | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Nov-09-21 | Initiated | Wolfe Research | Outperform |
Oct-22-21 | Initiated | Deutsche Bank | Sell |
Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-15-21 | Reiterated | Jefferies | Hold |
Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-09-20 | Downgrade | Needham | Buy → Hold |
Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-13-20 | Initiated | Jefferies | Buy |
Jun-30-20 | Initiated | Argus | Buy |
Jun-08-20 | Initiated | Barclays | Overweight |
Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Dec-03-19 | Resumed | BofA/Merrill | Buy |
Oct-25-19 | Initiated | ROTH Capital | Buy |
Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Hobbs Group Advisors LLC Purchases New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
MarketBeat
Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch
MarketWatch
Moderna, Inc. (NASDAQ:MRNA) is H&H International Investment LLC's 7th Largest Position - MarketBeat
MarketBeat
Profund Advisors LLC Buys 10,149 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
MarketBeat
Moderna marks trial win for next-gen COVID shot (NASDAQ:MRNA) - Seeking Alpha
Seeking Alpha
Moderna (NASDAQ:MRNA) Shares Down 2.2% on Insider Selling - Defense World
Defense World
Moderna Inc Stock (MRNA) Financials Data
Moderna Inc (MRNA) Revenue 2024
MRNA reported a revenue (TTM) of $5.08 billion for the quarter ending March 31, 2024, a -65.59% decline year-over-year.
Moderna Inc (MRNA) Net Income 2024
MRNA net income (TTM) was -$5.97 billion for the quarter ending March 31, 2024, a -224.75% decrease year-over-year.
Moderna Inc (MRNA) Cash Flow 2024
MRNA recorded a free cash flow (TTM) of -$3.67 billion for the quarter ending March 31, 2024, a -700.00% decrease year-over-year.
Moderna Inc (MRNA) Earnings per Share 2024
MRNA earnings per share (TTM) was -$15.67 for the quarter ending March 31, 2024, a -235.44% decline year-over-year.
Moderna Inc Stock (MRNA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
AFEYAN NOUBAR | Director |
Jun 12 '24 |
Sale |
147.20 |
15,000 |
2,208,071 |
2,314,015 |
AFEYAN NOUBAR | Director |
Jun 11 '24 |
Sale |
148.34 |
202,832 |
30,087,339 |
1,528,557 |
Klinger Shannon Thyme | Chief Legal Officer |
Jun 10 '24 |
Sale |
148.09 |
5,178 |
766,785 |
15,947 |
AFEYAN NOUBAR | Director |
Jun 05 '24 |
Sale |
151.25 |
15,000 |
2,268,804 |
1,946,931 |
Mock James M | Chief Financial Officer |
Jun 03 '24 |
Sale |
140.72 |
691 |
97,237 |
6,506 |
Hoge Stephen | President |
Jun 03 '24 |
Sale |
140.72 |
339 |
47,704 |
1,472,089 |
Klinger Shannon Thyme | Chief Legal Officer |
Jun 03 '24 |
Sale |
140.72 |
122 |
17,168 |
10,878 |
AFEYAN NOUBAR | Director |
May 29 '24 |
Sale |
145.08 |
20,000 |
2,901,585 |
1,961,931 |
Hoge Stephen | President |
May 29 '24 |
Sale |
144.50 |
341 |
49,276 |
1,471,777 |
Mock James M | Chief Financial Officer |
May 29 '24 |
Sale |
144.50 |
183 |
26,444 |
5,871 |
About Moderna Inc
Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):